Genitourinary Cancers Symposium Annual Meeting Coverage
Pembrolizumab, a PD-1 inhibitor, demonstrated antitumor activity in patients with high-risk BCG-unresponsive carcinoma in situ.
Trimodal therapy for patients with muscle-invasive bladder cancer is associated with worse cancer-specific and overall survival and higher costs compared with radical cystectomy.
Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported.
In a study of patients receiving non-surgical treatment for localized upper tract urothelial carcinoma, radiation or chemotherapy provided no overall survival benefit.
About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab.
Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status.
New analysis shows that early tumor shrinkage with cabozantinib is associated with longer survival compared with everolimus.
Patients with treatment-naive, intermediate- and poor-risk advanced RCC continue to have superior overall survival with the dual ICI regimen compared with sunitinib alone.
As first-line therapy for locally advanced or metastatic renal cell carcinoma, pembrolizumab plus axitinib offers longer overall and progression-free survival compared with sunitinib.
Obese men treated with docetaxel for metastatic castration-resistant prostate cancer have longer cancer-specific and overall survival, a study found.
Study shows that black men with metastatic castration-resistant prostate cancer may be experiencing a delay in receiving radium-223 compared with nonblack men.
Among men receiving radiation therapy for prostate cancer, the proportion of those receiving brachytherapy dropped from 59.3% to 34.7% from 2004 to 2014, a study found.
Abiraterone, Prednisone With Androgen Deprivation Therapy Show Durable Efficacy in Metastatic Castration-Naive Prostate Cancer
At a median follow-up of nearly 52 months, the treatment regimen deceased mortality risk among men with high-risk metastatic castration-naive prostate cancer by 30%.
By targeting prostate-specific membrane antigen, a molecule radiolabeled with lutetium-177 is expected to deliver high doses of beta radiation to distant metastases.
After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)